Bernadett Miriam Dobai

Bernadett Miriam Dobai


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BDBernadett Miriam Dobai
Bernadett Miriam Dobai
BPBalazs Polgar
Balazs Polgar
MGMárk Gémesi
Márk Gémesi
MBManuella Bogdan
Manuella Bogdan
NVNikolett Vigh
Nikolett Vigh
PBPeter Bogyi
Peter Bogyi
Background/Objectives: Pacemaker-induced cardiomyopathy (PICM) develops in up to 30% of patients with chronic right ventricular pacing. While biventricular (BIV) upgrade is the conventional strategy, conduction system pacing (CSP) offers a physiologic alternative recently endorsed by the 2025 ESC/EHRA Consensus Statement. However, comparative evidence in PICM is limited. Therefore, we aimed to compare outcomes of PICM patients undergoing CSP versus BIV upgrade. Methods: This retrospective analysis included consecutive PICM patients who were upgraded to CSP or BIV between 2022 and 2024 at a single, experienced center. Follow-up averaged >19 months. Clinical outcomes, lead performance, echocardiographic parameters, complications, and quality of life (QoL) were evaluated. Results: Sixty-three patients were included (CSP: 26; BIV: 37). Mean age and sex distribution were similar; both groups had wide paced QRS complexes and a high ventricular pacing burden. Baseline left ventricular ejection fraction (LVEF) was lower in BIV patients (29 ± 7% vs. 35 ± 6%, p = 0.01). Procedure duration was comparable, but fluoroscopy was shorter with CSP. QRS duration narrowed significantly in both groups (CSP: 163 ± 28→132 ± 12 ms; BIV: 171 ± 23→140 ± 18 ms; both p < 0.05). During follow-up, LVEF improved (CSP: 41 ± 8%; p = 0.008; BIV: 39 ± 8%, p = 0.0001), as did NYHA class, with no significant intergroup differences. The rates of heart failure hospitalization, all-cause mortality, and QoL were similar. Notably, 34.6% of CSP patients retained their existing generator, suggesting procedural and economic benefits. Conclusions: CSP is a feasible and potentially cost-efficient alternative to BIV upgrade in PICM, with comparable improvements in ventricular function, symptoms, and clinical outcomes. Larger prospective trials are warranted.

11 November 2025 in HeartRhythm Case Reports
Verified
Journal Article
Open access
BDBernadett Miriam Dobai
Bernadett Miriam Dobai
EZElőd János Zsigmond
Előd János Zsigmond
MTMirjam Franciska Turáni
Mirjam Franciska Turáni
MBManuella Bogdan
Manuella Bogdan
GDGábor Zoltán Duray
Gábor Zoltán Duray
PBPeter Bogyi
Peter Bogyi